This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: H18.6 | Special Copayment Reduction: V307 (5 years) |
| B. Synonyms | Keratoconus, keratectasia, KC |
| C. Adult onset | High likelihood of first onset in adulthood — onset in the teens~30s, with a tendency for natural progression to stop after the 40s; first diagnosis in early adulthood is common |
| 1. History | First described by Nottingham (1854); advances in contact lens fitting in the 20th century; the paradigm of halting progression established with the clinical introduction of CXL (Dresden protocol) in 2003 |
| 2. Causes | Weakening of collagen cross-links in the corneal stroma → conical protrusion → progression of irregular astigmatism and myopia; eye rubbing, atopy and long-term contact lens wear are aggravating factors |
| 3. Genetics | VSX1, COL4A3, LOX, ZNF469, COL5A1, FOXO1, WNT10A, MIR184; autosomal dominant (incomplete penetrance) or sporadic; polygenic contribution confirmed by GWAS |
| 4. Epidemiology | Worldwide prevalence about 1/2,000; relatively high prevalence reported in Asia including Korea; slight male predominance; onset in the teens~30s |
| 5. Pathophysiology | Abnormal arrangement of stromal collagen fibers, reduced LOX enzyme activity, MMP overactivity, oxidative stress → stromal thinning → conical protrusion due to intraocular pressure |
| 6. Symptoms | Progressive myopia and irregular astigmatism, monocular diplopia, light scattering, night glare; corneal opacity and acute hydrops with progression |
| 7. Signs | Munson sign (V-shaped protrusion of the lower eyelid), Rizutti sign, decreased corneal thickness, Vogt striae, Fleischer ring (iron pigment deposition) |
| 8. Screening | Scheimpflug corneal topography (Pentacam), keratometry; exclusion of keratoconus essential before refractive surgery; early examination of risk groups with atopy and eye rubbing |
| 9. Diagnosis | Corneal topography (K-max >47 D, asymmetric bowtie), anterior segment OCT (minimum corneal thickness), ABT index; Amsler-Krumeich classification applied |
| 10. Treatment | Halting progression: corneal collagen cross-linking (CXL, Dresden/accelerated); vision correction: glasses → RGP lenses → scleral lenses; surgery: DALK/PKP; Intacs intracorneal ring |
| 11. Prognosis | Progression halted in about 90% after CXL; corneal transplantation can be avoided with early treatment; satisfactory vision can be maintained with scleral lenses after natural stabilization in the 40s |
| 12. Prevention | Education to avoid eye rubbing (most important), active treatment of atopy, timely CXL, essential corneal topography screening before refractive surgery |
| 13. References | 10 references listed with PMID/DOI (below) |
The clinical entity of keratoconus was first established in 1854 when John Nottingham of England systematically described conical protrusion of the cornea and irregular astigmatism. Later, in 1869, John Bowman added a detailed clinical description of this disease. In the 1920s, when the slit lamp was introduced, characteristic clinical signs such as Vogt's striae and the Fleischer ring were described, and from the mid-20th century rigid gas-permeable contact lenses (RGP) became established as a means of optical correction of irregular astigmatism.
As corneal topography technology advanced in the 1980s~90s, early diagnosis of the subclinical stage of keratoconus became possible, and this came to play a decisive role in selecting indications for refractive surgery (LASIK/PRK). The most groundbreaking therapeutic advance was corneal collagen cross-linking (CXL; riboflavin+UVA), developed in Dresden, Germany, in 2003. The Dresden protocol published by Wollensak, Seiler, Spoerl et al. demonstrated that it effectively halts progression by increasing the cross-linking strength of the keratoconic stroma, and it subsequently became the standard treatment worldwide. With US FDA approval in 2016 (KXL system), the official indication was established, and FDA approval of epithelium-on (epi-on) CXL is also expected around 2025.
The core cause of keratoconus is weakening of the crosslinks between collagen fibers in the corneal stroma and the resulting failure of stromal thickening. In the normal corneal stroma, collagen lamellae are uniformly arranged and resist intraocular pressure, but in keratoconus, stromal strength is weakened by nonuniform arrangement of lamellae, reduced collagen fiber diameter, decreased numbers of stromal cells (keratocytes), reduced lysyl oxidase (LOX) activity, etc.
Among the main aggravating factors, eye rubbing is regarded as the most powerful environmental factor. Eye rubbing weakens collagen bonds through mechanical shear forces and releases inflammatory mediators (IL-6, TNF-α) and matrix-degrading enzymes (MMP-1, -3, -9, -13), accelerating stromal damage. The markedly high prevalence of keratoconus in patients with atopic dermatitis and allergic conjunctivitis is directly linked to chronic eye-rubbing behavior. Long-term contact lens wear and sleep disorders (sleeping positions that press on the eyes while lying face down) have also been proposed as contributing factors.
A family history is identified in about 10% of keratoconus cases, and the high concordance in identical twins makes the genetic contribution clear. However, it is a polygenic disease that cannot be explained by a single causative gene.
Epigenetic studies have confirmed that abnormal DNA methylation, dysregulation of miR-143, miR-182 and miR-184, and disruption of lncRNA networks contribute to stromal remodeling in keratoconus. In patients with Down syndrome (trisomy 21), the prevalence of keratoconus is about 5~8%, 10~15 times higher than in the general population, suggesting a genetic-developmental association.
The worldwide prevalence of keratoconus is reported as 1 in 1,000~2,000 depending on testing methods and diagnostic criteria, but in studies using corneal topography it is estimated as high as 1 in 500 (0.2%). Relatively higher prevalence than in the West is reported in the Middle East (Saudi Arabia, Iran: prevalence 0.4~2.3%) and Asia (including India and Korea).
The age of onset is typically the late teens~early 20s, progressing until the 30s with a tendency toward natural stabilization after the 40s. The sex distribution is reported as slightly male-predominant (male:female = 1.5:1 in some studies) or similar. About 90% are bilateral, but asymmetry is common, with one eye progressing first or more severely. Risk factors include family history, atopic dermatitis, allergic conjunctivitis, Down syndrome and connective tissue diseases (Ehlers-Danlos syndrome, Marfan syndrome).
The pathogenesis of keratoconus is explained by a complex interaction of weakened stromal structure and inflammatory and oxidative pathways.
Reduced LOX enzyme activity decreases the formation of pyrrolidine and pyridinoline crosslinks of collagen and elastin, lowering the mechanical strength of the stroma. Abnormal arrangement of collagen lamellae (interlamellar slippage and separation) and reduced adhesion between lamellae create localized weak areas that form the basis of conical protrusion due to intraocular pressure.
Increased expression of MMP-1, -3, -9 and -13 and decreased expression of TIMP (tissue inhibitors of metalloproteinases) are observed in the keratoconic stroma. This causes direct degradation of collagen fibrils, accelerating stromal thinning. Inflammatory cytokines such as IL-1α/β, TNF-α and IL-6 also form a feedback loop that increases MMP secretion.
In keratoconic corneas, decreased expression of antioxidant enzymes such as catalase and SOD and accumulation of ROS are observed. Oxidative stress induces apoptosis of stromal cells (keratocytes), reducing collagen production capacity, and decreased anterior stromal cell density accelerates corneal thinning. The mechanical stimulation of eye rubbing induces IL-1α release from corneal epithelial cells, acting as a trigger that activates all of the pathways described above.
The symptoms of keratoconus worsen gradually as changes in corneal shape progress.
On the Pentacam Scheimpflug camera, increased anterior and posterior corneal curvature (K-max >47 D), an asymmetric bowtie astigmatism pattern and decreased minimum corneal thickness are the key diagnostic findings. A 'scissors reflex' is observed on retinoscopy.
Screening for keratoconus is essential in high-risk groups and candidates for refractive surgery.
The diagnosis of keratoconus combines clinical findings and corneal topography.
In vivo confocal microscopy (IVCM) shows Bowman's layer abnormalities, decreased stromal cell density and abnormal nerve fiber arrangement. OCT-based anterior segment imaging precisely measures layer-by-layer thickness. The Ocular Response Analyzer (ORA) measures corneal biomechanical indices (corneal hysteresis, CRF) — markedly reduced in keratoconus.
The natural course of keratoconus varies greatly between individuals, but the prognosis improves markedly when CXL is performed early. After CXL treatment, halting of progression is confirmed in about 90%, and in some, a decrease in K-max (mean 1~2 D) and an increase in minimum corneal thickness are observed. If progression is successfully halted, vision at a level correctable with scleral lenses can be maintained long term.
Long-term outcomes of corneal transplantation (DALK/PKP) are good, with 10-year graft survival of about 90% or more. DALK has almost no endothelial rejection but is technically demanding, and conversion to PKP is needed if Descemet's membrane is perforated. If the scar after acute hydrops does not involve the visual axis, observation without transplantation is possible. When natural stabilization occurs after the 40s, some patients maintain satisfactory vision with scleral lenses even without CXL. Correction of eye-rubbing behavior is the most important modifiable factor for long-term prognosis.
Complete primary prevention of keratoconus is impossible, but the following measures are key to halting progression and preventing complications.